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Background
In a prior study of patients with diabetes, diastolic function was similarly 
impaired in masked hypertension (MHT) and sustained hypertension 
(SHT). We evaluated whether MHT is associated with impaired diastolic 
function compared with SHT and sustained normotension (NT) in the 
general population.
Methods
From February 2005 to December 2010, 798 participants without 
a history of cardiovascular disease or treated hypertension, were 
enrolled in the Masked Hypertension Study. Participants underwent 
clinic blood pressure (CBP) and 24-hour ambulatory blood pressure 
(ABP) measurements. A  2-dimensional Doppler echocardiogram 
was performed to evaluate diastolic function,s cardiac structure, 
volume, and systolic function. The 9 CBPs obtained across 3 clinic 
visits and awake ABP measurements were averaged. Clinic hyper-
tension was defined as systolic/diastolic blood pressure (SBP/DBP) ≥ 
140/90 mmHg. Ambulatory hypertension was defined as awake SBP/
DBP ≥ 135/85 mm Hg. MHT was defined as having ambulatory but not 
clinic hypertension. White-coat hypertensives (n = 8) were excluded 
from the analysis.
results
Of the 790 participants, 116 (14.7%) participants had MHT, 37 (4.7%) par-
ticipants had SHT, and 637 (80.6%) participants had NT. After age, sex, 
race/ethnicity, and body mass index adjustment, compared with NT, 
E’-velocities were significantly lower in MHT (P < 0.01) and SHT (P < 0.05), 
and E/E’ ratios were significantly higher MHT (P < 0.05) and SHT (P < 0.05). 
These associations were independent of left ventricular mass. Diastolic 
function parameters did not significantly differ between MHT and SHT.
conclusions
Diastolic function was impaired in MHT compared with NT independ-
ent of changes in left ventricular mass.
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The term masked hypertension (MHT)1 is used to describe 
individuals with clinic blood pressure (CBP) in the normal 
range (<140/90 mm Hg) but elevated awake ambulatory 
blood pressure (ABP; ≥135/85 mm Hg). The prevalence of 
MHT is estimated to be between 8% and 20% in the gen-
eral adult population.2 Individuals with MHT have been 
shown to have a higher risk of cardiovascular events than 
individuals with sustained normotension (NT), defined as 
having normal CBP and normal ABP (<135/85 mm Hg) 
and similar cardiovascular risk compared with individuals 
with sustained hypertension (SHT), defined as having clinic 
hypertension (HT; ≥140/90 mm Hg) and elevated ABP 
(≥135/85 mm Hg).3–6 Previous cross-sectional studies have 
shown that participants with MHT have higher levels of left 
ventricular mass (LVM)7, 8 and a higher likelihood of con-
centric remodeling,4, 9 compared with individuals with NT.
Impaired diastolic function is a common finding in HT.10 
It may occur in the absence of left ventricular hypertrophy 
(LVH) in HT11 and may even occur before the development 
of HT and LVH.12 In a sample of 71 clinic outpatients with 
diabetes, Marchesi et al.13 showed that LVM increased pro-
gressively from NT to MHT to SHT, whereas diastolic func-
tion was found to be similarly impaired in MHT and SHT 
compared with NT. Because individuals with MHT may be 
at increased risk of developing SHT,14 we hypothesized that 
an alteration of diastolic function may be present in MHT 
compared with NT in a population with a wider range of car-
diovascular disease risk. We also hypothesized that diastolic 
function may be similarly impaired in MHT compared with 
SHT. The primary aim of this study was to evaluate left ven-
tricular (LV) diastolic function as well as cardiac structures, 
volumes, and systolic function in MHT compared with NT 
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and SHT among participants from the Masked Hypertension 
Study, an ongoing, worksite-based study.
Methods
study population
The Masked Hypertension Study, an ongoing, worksite-
based study of the prevalence, predictors, and prognosis 
of MHT, is comprised of adult employees who work for 
> 20 hours/week, including at least 2 consecutive days. 
Participants were recruited from 2 large universities with 
medical schools (Stony Brook University and Columbia 
University) and affiliated teaching hospitals, as well as a 
private hedge fund management organization. The cur-
rent analysis includes 798 participants who were enrolled 
between February 2005 and December 2010. Exclusion 
criteria included any of the following: a screening clinic 
systolic blood pressure (SBP) > 160 mm Hg or diastolic 
blood pressure (DBP) > 105 mm Hg, evidence of secondary 
hypertension other than a history of pregnancy-induced 
hypertension, taking antihypertensive medications or 
other medications that are known to affect blood pressure 
(e.g., steroids, tricyclic antidepressants), overt cardiovas-
cular disease, history of chronic renal disease, liver dis-
ease, adrenal disease, thyroid disease, were pregnant, or 
reported active substance abuse or a severe debilitating 
psychiatric disorder. The blood pressure eligibility crite-
rion for this study was chosen to obtain a sample with a 
wide distribution of untreated blood pressures. For safety 
reasons, we referred participants immediately to their 
physicians for further management if their screening CBP 
was > 160/105 mm Hg. Information about demographics 
(age, sex, race, ethnicity), height, weight, cardiovascular 
risk factors, and family history of risk factors were ascer-
tained from all participants. Written informed consent was 
obtained from all participants. The study was approved by 
the institutional review boards of Columbia University 
and Stony Brook University.
Blood pressure assessments
Participants attended 5 visits over a 4-week period. 
During the first 3 visits (visit 1–3), which usually occurred 
within a 3-week period, the participant was escorted into 
an examination room and asked to rest comfortably in the 
seated position, with legs uncrossed, for at least 5 minutes. 
A  research nurse/technician then obtained 3 consecutive 
CBP readings, separated by at least 1 minute, using a mer-
cury sphygmomanometer (W.A. Baum, Copiague, NY) and 
stethoscope. Thus, a total of 9 CBP readings were available 
for each participant. On visit 3, the participant was fitted 
with an appropriate-sized arm cuff for a Spacelabs ambu-
latory blood pressure monitor (Model 90207; Redmond, 
WA). ABP measurements were taken at 28-minute intervals 
throughout the subsequent 24-hour monitoring period. 
The recording was analyzed to obtain average awake SBP 
and DBP levels based on sleep/wake times defined by 
data obtained from an actigraphy monitor worn on the 
wrist (ActiWatch; Phillips Respironics, Murrayville, PA), 
supplemented by diary reports of the times participants 
woke up and went to sleep. The next day (visit 4) partici-
pants returned the ambulatory blood pressure monitor and 
the actigraphy monitor.
hypertension classification
For purposes of the present analyses, participants were 
classified as having NHT, MHT, and SHT by CBP and ABP 
measurements. For the primary analysis, the 9 CBP readings 
from the 3 clinic visits were averaged. Clinic HT was defined 
as mean SBP ≥ 140 mm Hg or mean DBP ≥ 90 mm Hg. 
Ambulatory HT, based on mean awake ABP, was defined as 
mean SBP ≥ 135 mm Hg or mean DBP ≥ 85 mm Hg, which 
are internationally accepted limits.15, 16 MHT was defined 
as having CBP in the normal range (SBP < 140 mm Hg and 
DBP < 90 mm Hg) and ambulatory HT. SHT was defined as 
having both clinic HT and ambulatory HT. NT was defined 
as having both normal CBP and normal ABP. White-coat 
hypertension (WCHT) was defined as having clinic HT and 
normal ABP.
two-dimensional and doppler echocardiographic measures
During visit 5, 2-dimensional and Doppler echocardi-
ography were performed and stored in a DICOM digital 
format for analysis. Cardiac measurements were obtained 
according to the recommendations of the American 
Society of Echocardiography (ASE). A  minimum of 3 
cardiac cycles was measured using an offline analysis 
package installed on a dedicated workstation (Syngo 
Dynamics version 7; Siemens Medical Systems, Mountain 
View, CA) and then averaged. Cardiac structures, vol-
umes, and LV function were assessed by 2-dimensional 
echocardiography. Interventricularseptal thickness dur-
ing diastole (IVSd), posterior wall thickness during 
diastole (PWTd), LV internal diameter during diastole 
(LVIDd), LV internal diameter during systole (LVIDs), 
and left atrial antero-posterior diameter (LAD) were 
obtained from long axis parasternal views. Fractional 
shortening percentage (FS%) was calculated using the fol-
lowing formula: FS% = 100 × (LVIDd − LVIDs) / LVIDd. 
LVM was calculated using the corrected ASE method: 
0.8 × (1.04 × [(IVSd + LVIDd + PWTd)3− LVIDd3]) + 
0.6. LVM index (LVMI) was calculated by dividing LVM 
by estimated body surface area, calculated from height 
and weight. The presence of LVH was defined as LVMI 
≥ 89 g/m2 for women and ≥ 103 g/m2 for men according 
to ASE guidelines.17 Relative wall thickness (RWT) was 
calculated using the following formula: RWT = (IVSd + 
PWTd) / LVIDd. LV end-diastole volume (LVEDV) and 
LV end-systole volume (LVESV) were obtained from 
apical 4-chamber and 2-chamber views using the modi-
fied Simpson rule. LV ejection fraction (LVEF) was cal-
culated using the following formula: LVEF (%) = 100 × 
(LVEDV − LVESV) / LVEDV. Transmitral flow by pulse-
wave Doppler was obtained from the apical 4-chamber 
view. The peak early (E-wave) and late (A-wave) diastolic 
filling velocities and E-wave deceleration time (E-DcT) 
were measured, and the E/A ratio was calculated. The 
810 American Journal of Hypertension 26(6) June 2013
Oe et al.
mitral annular motion velocity by tissue Doppler imag-
ing was obtained from the apical 4-chamber view. The 
averaged values at septal and lateral position were used 
for analysis. The peak early (E’-wave) and late (A’-wave) 
diastolic annular velocities were measured. The ratio of E 
to E’ (E/E’) was calculated to assess diastolic function. An 
impaired relaxation pattern occurs at early stage, which is 
characterized by lower E-wave, E/A ratio, and prolonged 
E-DcT.18 E’-wave of mitral annular velocity also decrease 
with impaired LV relaxation.19 E’-wave correlates with 
a variety of other invasively measured indexes such as 
tau, LV-dP/dt, and minimal LV pressure.19 E’/E ratio, the 
combination of mitral flow velocity and mitral annulus 
velocity, has been identified as the best parameter for 
diagnosis of diastolic dysfunction.20 It has shown to have 
a better correlation with the estimation of LV filling pres-
sure when compared with other Doppler measures.21
statistical analysis
Characteristics of the study population were calculated 
as mean ± SD or percentage. Echocardiographic measures 
were calculated for participants with NT, MHT, and SHT 
with differences across groups assessed using 1-way analy-
sis of variance with pairwise comparisons (Tukey honestly 
significant difference method). Analysis of covariance with 
pairwise comparisons (Tukey honestly significant difference 
method) was used to evaluate differences in echocardio-
graphic measures after adjusting for age, sex, race/ethnicity, 
and body mass index (BMI). BMI was calculated as body 
weight in kilograms divided by the square of the height in 
meters. To explore whether group differences in diastolic 
parameters were explained by LVMI, the analyses of dias-
tolic function parameters were repeated after adding LVMI 
to an age-, sex-, race/ethnicity-, and BMI-adjusted model. 
Analyses of diastolic function parameters were also repeated 
after adding heart rate during the echocardiogram and LVEF 
to an age-, sex-, race/ethnicity-, and BMI-adjusted model. 
Statistical analyses were performed using SAS version 9.2 
(SAS Institute, Cary, NC).
results
study population
Figure 1 shows the distribution of participants by CBP and 
ABP categories. Among the final sample of 790 participants, 
637 (80.6%) had NT, 116 (14.7%) had MHT, and 37 (4.7%) 
had SHT. Table 1 shows baseline characteristics of the entire 
sample (N = 790) and by group (NT, MHT, and SHT). The 
prevalence of LVH was 2.5% in the study sample (N = 790) 
and 1.7%, 4.3%, and 10.8% in participants with NT, MHT, 
and SHT respectively.
cardiac structure, volume, and function in Mht, sht, and nt
Table 2 shows the mean levels of cardiac structures, vol-
umes, LV function, and diastolic function for participants 
with NHT, MHT, and SHT in unadjusted (top panel) and 
adjusted (lower panel) models. In unadjusted models, LVIDs 
was significantly smaller, and FS%, LVEDV, LVM, LVMI, 
and RWT were significantly greater in participants with SHT 
than in participants with NT. LVM, LVMI, and RWT were 
significantly greater in participants with MHT than in par-
ticipants with NT. Further, LVIDs was significantly greater 
and FS%, LVM, LVMI, and RWT were significantly lower 
in participants with MHT compared with participants with 
SHT. There were no significant differences in LVIDd, LVESV, 
and LVEF among the 3 groups.
In age-, sex-, race/ethnicity-, and BMI-adjusted models, 
LVIDs was significantly smaller and FS%, LVM, LVMIm 
and RWT were significantly greater in participants with 
SHT than in participants with NT. There were no significant 
adjusted differences in these echocardiographic parameters 
between participants with MHT and participants with NT. 
LVIDs was significant higher and FS% and RWT were 
Figure 1. Participant categories defined by clinic and ambulatory blood pressure (BP). On the basis of clinic BP and ambulatory BP, the 798 participants 
were categorized into 4 groups: sustained normotension, masked hypertension, white-coat hypertension, and sustained hypertension. The participants 
(n = 8) with white-coat hypertension were excluded from the current analysis, which left a final sample size of 790.
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significantly lower in participants with MHT compared 
with participants with SHT. None of the other measures, 
including LVIDd, LVEDV, LVESV, and LVEF, differed sig-
nificantly across the 3 groups in adjusted models.
diastolic function in Mht, sht, and nt
Table  3 shows diastolic function parameters for those 
with NHT, MHT, and SHT in unadjusted (top panel) and 
adjusted (lower panel) models. In unadjusted models, par-
ticipants with SHT had significantly greater LAD, A-wave, 
and E/E’ ratio and significantly lower E/A ratio and E’-wave 
compared with participants with NT. Participants with MHT 
had significantly greater LAD, A-wave, and E/E’ ratio and 
significantly lower E/A ratio and E’-wave than participants 
with NT. None of the diastolic function parameters differed 
significantly between participants with MHT and partici-
pants with SHT. Finally, there were no differences among the 
3 groups in 3 of the diastolic function parameters: E-wave, 
E-DcT, and A’-wave.
In age-, sex-, race/ethnicity-, and BMI-adjusted models, 
participants with SHT and MHT had lower E’-wave and 
higher E/E’ ratio than participants with NT. These parame-
ters were not statistically different between participants with 
MHT and participants with SHT. Further, participants with 
SHT had greater A-wave than participants with NT, but this 
difference was not statistically significant (P = 0.06). None 
of the other measures of diastolic function—LAD, E-wave, 
A-wave, E/A ratio, E-DcT, and A’-wave—differed signifi-
cantly across the 3 groups. The associations of age, sex, race/
ethnicity, and BMI with each of the diastolic function param-
eters in an adjusted model are shown in Supplementary 
Table S1.
To explore whether group differences in diastolic 
parameters were explained by LVMI, the analyses of 
diastolic function parameters were repeated after adding 
LVMI to an age-, sex-, race/ethnicity-, and BMI-adjusted 
model. After further adjustment for LVMI, the results 
were similar to the age-, sex-, race/ethnicity-, and BMI-
adjusted model. In participants with SHT, E’-wave was 
Table 1. Characteristics of the Masked Hypertensive Study participants included in this analysis 
Characteristics Total (N = 790) NT (n = 637) MHT (n = 116) SHT (n = 37)
Age, y 45.5 ± 10.3 44.8 ± 10.3 48.0 ± 9.6 49.6 ± 1.0
Sex, % male 40.8 35.8 59.5 67.6
Race/ethnicity
  % Black 6.5 5.7 9.5 10.8
  % Hispanic 10.8 11.5 6.9 10.8
Body mass index, kg/m2 27.5 ± 5.3 27.2 ± 5.3 28.5 ± 5.0 30.2 ± 4.7
History of high cholesterol, % 26.7 25.6 25.9 48.6
History of diabetes, % 3.7 4.1 0.9 5.4
Current smoking, % 7.7 7.9 6.9 5.6
Family history of hypertension, % 66.3 66.4 65.5 66.7
Clinic (mean of 9 readings, taken during 3 visits)
  Systolic blood pressure, mm Hg 116 ± 12 113 ± 10 125 ± 8 142 ± 9
  Diastolic blood pressure, mm Hg 75 ± 8 73 ± 6 81 ± 5 91 ± 6
  % Hypertensivea 4.7 0 0 100.0
Mean awake on 24-hour ABPM
  Systolic blood pressure, mm Hg 123 ± 10 120 ± 8 135 ± 7 143 ± 8
  Diastolic blood pressure, mm Hg 77 ± 8 75 ± 6 87 ± 5 90 ± 7
  % Hypertensiveb 19.4 0 100.0 100.0
Mean sleepc on 24-hour ABPM
  Systolic blood pressure, mm Hg 106 ± 11 104 ± 9 116 ± 10 123 ± 10
  Diastolic blood pressure, mm Hg 62 ± 8 73 ± 7 69 ± 6 73 ± 9
  % Hypertensived 11.3 5.2 28.4 64.7
Data are mean ± SD unless otherwise noted. 
Abbreviations: ABPM, ambulatory blood pressure monitoring; MHT, masked hypertension; NT, sustained normotension; SHT, sustained 
hypertension.
aDefined by systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg.
bDefined by systolic blood pressure ≥ 135 mm Hg or diastolic blood pressure ≥ 85 mm Hg.
cMean sleep ABP was not calculated for 76 participants with < 4 sleep readings.
dDefined by systolic blood pressure ≥ 120 mm Hg or diastolic blood pressure ≥ 80 mm Hg.
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significantly lower (P = 0.01) and E/E’ ratio and A-wave were 
significantly higher (P = 0.006 and P = 0.048, respectively) 
than in participants with NT. In participants with MHT, 
E’-wave was significantly lower (P  =  0.003) and E/E’ ratio 
was significantly higher (P  =  0.008) than in participants 
with NT. There were no significant differences in A-wave, 
E’-wave, and E/E’ ratio between participants with MHT 
and participants with SHT. None of the other measures of 
diastolic function—LAD, E-wave, E/A ratio, E-DcT, and 
A’-wave—differed significantly across the 3 groups. Finally, 
after adding heart rate during the echocardiogram and LVEF 
to an age-, sex-, race/ethnicity-, and BMI-adjusted model, 
the results also did not change (not shown).
discussion
The results of our study indicate that tissue Doppler-
derived diastolic function parameters, specifically E’-wave 
and E/E’ ratio, are impaired in individuals with MHT com-
pared with individuals with NT and were similar for indi-
viduals with MHT and individuals with SHT. These findings 
suggest that alterations in diastolic function are observed in 
asymptomatic individuals with MHT at a level that is similar 
to individuals with SHT.
The findings of altered diastolic function in our study, 
which included generally healthy individuals with a wide 
range of cardiovascular disease risk, are consistent with 
a small clinical study of diabetic outpatients by Marchesi 
et al.13 which showed that although LVMI increased pro-
gressively from NT to MHT to SHT, diastolic function 
defined by E/A ratio, E’/A’ ratio, and E-DcT was found to 
be similarly impaired in MHT and SHT compared with NT. 
As mentioned previously, parameters driven from mitral 
inflow, such as E/A ratio and E-DcT, reflect abnormal LV 
relaxation, but they may be affected by left atrial pressure, 
heart rate, and mitral valve disease.22 E’/A’ ratio driven 
from tissue Doppler imaging is minimally affected by 
preload, and a previous study demonstrated that E’/A’ ratio 
correlates with LV relaxation.18 However, it is not com-
monly used and currently not recommended by the ASE.23 
In contrast, E’-wave and E/E’ ratio, which were altered in 
participants with MHT in our study, are recommended 
by the ASE for the assessment of diastolic function.23 E/E’ 
reflects the degree of LV filling pressure and is presently 
Table 2. Unadjusted and age-, sex-, race/ethnicity-, and body mass index–adjusted analyses comparing cardiac structures, volumes, and 
left ventricular function parameters between participants with masked hypertension (MHT), sustained hypertension (SHT), and sustained 
normotension (NT) 
Parameters
NT (n = 637) MHT (n = 116) SHT (n = 37) NT vs. MHT NT vs. SHT MHT vs. SHT
Mean (95% CI) P values
Unadjusted (ANOVA)
LVIDd, cm 4.54 (4.50–4.58) 4.63 (4.53–4.73) 4.44 (4.26–4.61) 0.23 0.48 0.13
LVIDs, cm 3.05 (3.01–3.09) 3.09 (3.00–3.18) 2.83 (2.66–2.99) 0.72 <0.05 <0.05
FS, % 32.9 (32.3–33.4) 33.4 (32.1–34.8) 35.8 (33.4–38.3) 0.72 <0.005 <0.05
LVEDV, ml 91 (89–93) 94 (90–99) 101 (94–109) 0.36 <0.05 0.26
LVESV, ml 32 (31–33) 34 (32–36) 37 (33–40) 0.32 0.07 0.43
LVEF, % 64.9 (64.4–65.3) 64.4 (63.3–65.5) 64.3 (62.4–66.3) 0.70 0.87 0.99
LVM, g 115 (112–117) 132 (125–139) 155 (143–167) <0.0001 <0.0001 <0.005
LVMI, g/m2 61.2 (60.0–62.3) 66.9 (64.2–69.7) 75.0 (70.1–79.8) <0.001 <0.0001 <0.01
RWT, % 35.1 (34.2–35.8) 37.7 (35.8–39.6) 49.2 (45.7–52.6) <0.05 <0.0001 <0.0001
Age-, sex-, race/ethnicity-, and body mass index–adjusted analyses (ANCOVA)
LVIDd, cm 4.56 (4.52–4.60) 4.57 (4.48–4.66) 4.38 (4.22–4.54) 0.95 0.09 0.09
LVIDs, cm 3.06 (3.03–3.10) 3.05 (2.96–3.14) 2.76 (2.60–2.91) 0.95 <0.001 <0.005
FS, % 32.8 (32.2–33.4) 33.4 (32.1–34.8) 37 (34.6–39.4) 0.63 <0.005 <0.05
LVEDV, ml 92 (90–93) 90 (86–94) 91 (90–93) 0.62 0.97 0.95
LVESV, ml 33 (32–33) 32 (30–34) 33 (29–36) 0.93 0.99 0.97
LVEF, % 64.9 (64.4–65.4) 64.6 (63.5–65.7) 64.6 (62.6–66.7) 0.89 0.98 0.99
LVM, g 116 (114–119) 122 (116–127) 134 (125–143) 0.18 <0.005 0.06
LVMI, g/m2 61.8 (60.7–62.8) 64.0 (61.5–66.6) 69.6 (65.1–74.1) 0.24 <0.005 0.08
RWT, % 35.3 (34.6–36) 36.2 (34.6–37.9) 43 (40–46) 0.55 <0.005 <0.0005
Bolded P values identify statistically significant differences between groups. 
Abbreviations: ANCOVA, analysis of covariance; ANOVA, analysis of variance; CI, confidence interval; FS, fractional shortening; LVEDV, left 
ventricular end-diastole volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVIDd, left ventricular inter-
nal diameter during end diastole; LVIDs, left ventricular internal diameter during end systole; LVM, left ventricular mass; LVMI, left ventricular 
mass index; RWT, relative wall thickness.
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recognized as the gold-standard index to detect diastolic 
dysfunction.20
In our study, the association of MHT with diastolic func-
tion was also independent of LVMI, suggesting that MHT-
associated changes in diastolic function are not explained by 
increases in LVMI. Several studies of patients with HT have 
shown that diastolic dysfunction may occur in the absence 
of LVH.11, 24 A clinical study of Nigerians with newly diag-
nosed HT11 demonstrated that impaired diastolic function 
occurs in approximately 60% of hypertensive individu-
als with LVH and 40% of hypertensive individuals without 
LVH. Similarly, a study by Aeschbacher et al.12 demonstrated 
that impaired diastolic function was detected in the young, 
normotensive male offspring of hypertensive parents before 
the development of LVH. A study by Mineeva et al.25 dem-
onstrated that altered transmitral blood flow is observed at 
the prehypertension stage that precedes heart remodeling. 
Consistent with these previous findings in HT patients, our 
results suggest that impaired diastolic function may be an 
early subclinical alteration seen in individuals with MHT 
before the development of LV structural changes. The mech-
anisms underlying the impairment in diastolic function 
independent of changes in LVMI associated with MHT are 
unknown. Although LVH induced by chronic pressure or 
volume overload may contribute to diastolic dysfunction,26 
other factors besides LVH are associated with impairment 
in diastolic function; these include contractile alterations in 
myocytes due to impaired sarcoplasmic reticulum calcium 
uptake, extracellular and perivascular fibrosis, and myo-
cardial ischemia.27–30 These mechanisms may have played a 
role in the association between MHT and impaired diastolic 
function in our study.
Diastolic heart failure as a consequence of impaired 
diastolic function in the general population is associated with 
a high mortality rate that is comparable with that of systolic 
heart failure mortality rates.31–33 Given the association 
between diastolic dysfunction and the subsequent 
development of heart failure,27 our findings suggest screening 
for diastolic dysfunction among individuals with MHT may 
be useful for the identification of an early phase of cardiac 
dysfunction. The follow-up of participants in the ongoing 
Masked Hypertension Study may eventually help determine 
whether or not E’-wave and E/E’ ratio have prognostic value 
for individuals with MHT.
Several limitations of this study should be acknowl-
edged. First, our sample consisted of employed adults who 
were generally healthy. Whether our results are generaliz-
able to other population-based or clinic-based samples 
remains unknown. Second, because awake ABP was esti-
mated from one 24-hour monitoring period, we cannot 
exclude the possibility that the study results would have 
differed with the inclusion of additional 24-hour periods to 
Table 3. Unadjusted and age-, sex-, race/ethnicity-, and body mass index–adjusted analyses comparing diastolic function parameters 
between participants with masked hypertension (MHT), sustained hypertension (SHT), and sustained normotension (NT) 
Parameters
NT (n = 637) MHT (n = 116) SHT (n = 37) NT vs. MHT NT vs. SHT MHT vs. SHT
Mean (95% CI) P values
Unadjusted (ANOVA)
LAD, cm 3.41 (3.38–3.44) 3.58 (3.50–3.66) 3.58 (3.44–3.72) <0.001 <0.05 0.99
E-velocity, m/s 0.71 (0.70–0.72) 0.68 (0.65–0.71) 0.68 (0.63–0.73) 0.18 0.49 0.99
A-velocity, m/s 0.54 (0.53–0.55) 0.58 (0.55–0.61) 0.63 (0.57–0.68) <0.05 <0.005 0.28
E/A ratio 1.41 (1.37–1.44) 1.25 (1.17–1.33) 1.15 (1.01–1.29) 0.001 <0.005 0.48
E-DcT, ms 194 (191–197) 193 (186–199) 205 (193–216) 0.95 0.16 0.18
E’ velocity, m/s 0.133 (0.130–0.136) 0.117 (0.111–0.124) 0.110 (0.098–0.122) <0.0005 0.001 0.54
A’ velocity, m/s 0.112 (0.11–0.115) 0.120 (0.114–0.126) 0.124 (0.114–0.135) 0.05 0.08 0.76
E/E’ ratio 5.69 (5.55–5.83) 6.23 (5.90–6.57) 6.72 (6.13–7.31) <0.01 <0.005 0.33
Age-, sex-, race/ethnicity-, and body mass index–adjusted analyses (ANCOVA)
LAD, cm 3.44 (3.41–3.46) 3.49 (3.42–3.55) 3.39 (3.27–3.46) 0.33 0.73 0.31
E-velocity, m/s 0.71 (0.69–0.72) 0.70 (0.67–0.73) 0.71 (0.69–0.72) 0.94 0.99 0.99
A-velocity, m/s 0.54 (0.53–0.55) 0.57 (0.54–0.59) 0.59 (0.55–0.64) 0.09 0.06 0.60
E/A ratio 1.39 (1.36–1.42) 1.31 (1.24–1.38) 1.28 (1.16–1.41) 0.12 0.21 0.89
E-DcT, ms 194 (192–197) 190 (184–197) 201 (189–212) 0.51 0.55 0.27
E’ velocity, m/s 0.131 (0.128–0.134) 0.121 (0.114 –0.127) 0.116 (0.105–0.127) <0.01 <0.05 0.76
A’ velocity, m/s 0.113 (0.111–0.115) 0.116 (0.111–0.122) 0.118 (0.108–0.129) 0.57 0.60 0.94
E/E’ ratio 5.71 (5.58–5.84) 6.20 (5.88–6.51) 6.57 (6.01–7.14) <0.05 <0.05 0.47
Bolded P values identify statistically significant differences between groups. 
Abbreviations: ANCOVA, analysis of covariance; ANOVA, analysis of variance; A-wave, peak late diastolic filling velocity of mitral inflow; 
A’-wave, peak late diastolic mitral annular velocity; CI = confidence interval; E-DcT, E-wave deceleration time; E-wave, peak early diastolic filling 
velocity of mitral inflow; E’-wave, peak early diastolic mitral annular velocity; LAD, left atrial diameter.
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define MHT, SHT, and NT. Finally, because this is a cross-
sectional observational study, causality cannot be deter-
mined in our study.
Strengths of the study include a large sample size, the care-
ful assessment of CBP over 3 visits, the inclusion of a large 
proportion of participants with normal CBP levels who oth-
erwise would be classified as lower risk based on CBP, the 
exclusion of participants on antihypertensive medications, 
and the assessment of cardiac structures, volumes, and sys-
tolic and diastolic function using validated 2-dimensional 
and Doppler echocardiographic methods.
In conclusion, we demonstrated that diastolic func-
tion represented by E’-wave and E/E’ ratio was impaired in 
MHT compared with NT, even after controlling for LVMI. 
These data suggest MHT is associated with impaired dias-
tolic function in the absence of LV structural changes. The 
mechanisms underlying the association between MHT and 
impaired diastolic function and whether or not these sub-
clinical alterations have prognostic value for subsequent 
diastolic heart failure in MHT are unknown. Future stud-
ies are needed to evaluate the prognostic value of impaired 
diastolic function in MHT as well as promising interven-
tions targeting MHT-associated impaired diastolic function.
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